Radiotherapy for cutaneous squamous cell carcinoma: current standards and outlooks

Author:

Gevorkov A. R.1ORCID,Boyko A. V.1ORCID,Polyakov A. P.1ORCID,Chernichenko A. V.1ORCID,Gerasimov V. A.1ORCID,Meshcheryakova I. A.1ORCID,Kaprin A. D.2ORCID

Affiliation:

1. P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia

2. P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia; National Medical Research Center of Radiology, Ministry of Health of Russia; Рeoples’ Friendship University of Russia

Abstract

Cutaneous squamous cell carcinoma accounts for 20 % of all malignant non-melanoma skin tumors, which is one of the most common cancers worldwide. Antitumor treatment is usually very effective: cure rate reaches 90 %, while local recurrence rate is 25 %. The main treatment option for primary skin cancers is surgery. The most significant risk factors for locoregional recurrence include tumor location (head and neck), size (>2 cm), depth of invasion (>4 mm), tumor differentiation grade, perineural invasion, immune system disorders (immunosuppression), severe concomitant diseases, and previous treatment.In patients with advanced cutaneous squamous cell carcinoma, 1-year, 2-year, and 3-year survival rates are 50–80, 30–35 and 15–16 %, respectively. Radiotherapy is a radical treatment option that increases the 5-year survival rate to 90 % and ensures good cosmetic results in 80 % of cases. There are 3 main variants of radiotherapy for cutaneous squamous cell carcinoma: sole radiotherapy according to a radical program, adjuvant radiotherapy in combination with surgery, and palliative radiotherapy. most frequently, radiotherapy is used as part of adjuvant postoperative treatment and is not initially considered as a sole conservative treatment for cutaneous squamous cell carcinoma patients below 45 years of age with resectable tumors, especially high-risk tumors. palliative radiotherapy is an affordable and effective method for combating painful symptoms; moreover, it often provides long-term local control. 

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Otorhinolaryngology,Surgery

Reference77 articles.

1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3): 209–49. DOI: 10.3322/caac.21660

2. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, O.A. Shahzadova. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of “NMIC of Radiology”, Ministry of Health of Russia, 2021. (In Russ.)].

3. The state of oncological care to the population of Russia in 2020. Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of “NMIC of Radiology”, Ministry of Health of Russia, 2021. 239 p. (In Russ.).

4. Polyakov A.P., Gevorkov A.R., Stepanova A.A. Current strategy of squamous cell carcinoma diagnosis and treatment. Head and Neck Tumors 2021;11(1):51–72. (In Russ.). DOI: 10.17650/2222-1468-2021-11-1-51-72

5. Newman G., Hall M.A., Kurley S.J. et al. Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review. Head Neck 2021;43(9):2822–43. DOI: 10.1002/hed.26767

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3